Metastatic pancreatic cancer: Old drugs, new paradigms

Current Opinion in Oncology

Volumn 23, Issue 4, 2011, Pages 390-395

  Conroy, Thierry ^a   Gavoille, Céline ^a   Adenis, Antoine ^b  

^a CENTRE ALEXIS VAUTRIN   (France)

^b UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

Author keywords

chemotherapy; pancreatic cancer; targeted agents

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CONATUMUMAB; DOCETAXEL; EPIRUBICIN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; GANITUMAB; GEMCITABINE; HEPARIN; IRINOTECAN; MARIMASTAT; OXALIPLATIN; PACLITAXEL; TERTOMOTIDE; TIPIFARNIB;

ADVANCED CANCER; CANCER SURVIVAL; DIARRHEA; DRUG FORMULATION; HEMATOLOGIC DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; METASTASIS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RASH; REVIEW; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; FLUOROURACIL; HEPARIN; HUMANS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PANCREATIC NEOPLASMS; PLATINUM; QUINAZOLINES;

EID: 79958776238     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283473610     Document Type: Review

References (55)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin 2009; 59:225-249.
2. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995; 76:1671-1677.
3. Lefebvre AC, Maurel J, Boutreux S, et al. Pancreatic cancer: incidence, treatment and survival trends: 1175 cases in Calvados (France) from 1978. to 2002. Gastroenterol Clin Biol 2009; 33:1045-1051.
4. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593-600. (Pubitemid 26285639)
5. Sultana A, Smith CT, Cunningham D, et al. Meta-analysis of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25:2607-2615. (Pubitemid 47041235)
6. Chabot JA, Tsai WY, Fine RL, et al. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol 2010; 28:2058-2063.
7. Bruckner HW, Crown J, McKenna A, et al. Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors. Cancer Res 1988; 48:5570-5572.
8. Ducreux M, Mitry E, Ould-Kaci M, et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 2004; 15:467-473. (Pubitemid 38444551)
9. BurrisAH3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413. (Pubitemid 27251144)
10. Di Marco M, Di Cicilia R, Macchini M, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? Oncol Rep 2010; 23:1183-1192.
11. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-min infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern CooperativeOncology Group. J Clin Oncol2009; 27:3778-3785.
12. Kulke MH, Tempero M, Niedzwiecki D, et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol 2009; 27:5506-5512.
13. Ciccolini J, Dahan L, André N, et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicity in adults after gemcitabinebased chemotherapies. J Clin Oncol 2009; 27:1-6.
14. Spratlin J, Sangha R, Glubrecht D, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10:6956-6961. (Pubitemid 39383046)
15. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1. levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136:187-195.
16. Maréchal R, Mackey JR, Lai R, et al. Human equilibrative nucleoside transporter 1. and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009; 15: 2913-2919.
17. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27:5513-5518.
18. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25:2212-2217. (Pubitemid 46954645)
19. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-3516.
20. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27:2231-2237.
21. Conroy T, Desseigne F, Ychou M, et al. Randomized phase III trial comparing folfirinox (F: 5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs. gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). Final results of the PRODIGE 4 /ACCORD 11 trial [abstract 4010]. J Clin Oncol 2010; 28:303S.
22. Kindler HL, Richards DA, Stephenson J, et al. A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC) [abstract 4035]. J Clin Oncol 2010; 28:15s; 309s.
23. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patient with locally advanced and/or metastatic pancreatic carcinoma. Cancer 2002; 94:902-910.
24. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24:3946-3952. (Pubitemid 46630743)
25. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as firstline treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010; 28:1645-1651.
26. Takeda S, Shimazoe T, Kuga H, et al. Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11. Biochem Biophys Res Commun 1992; 188:70-77.
27. Bissery MC, Vrignaud P, Lavelle F, et al. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 1996; 7:437-460. (Pubitemid 26249198)
28. Sakata Y, Shimada Y, Yoshino M, et al. A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11. Study Group on Gastrointestinal Cancer. Gan To Kagaku Ryoho 1994; 21:1039-1046. (Pubitemid 24225032)
29. Wagener DJT, Verdonk HER, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995; 6:129-132.
30. Ueno H, Okusaka T, Funakoshi A, et al. A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2007; 59:447-454. (Pubitemid 46127378)
31. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22:3776-3783. (Pubitemid 41095218)
32. Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006; 95:587-592. (Pubitemid 44325898)
33. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006; 24:4441-4447. (Pubitemid 46630982)
34. Von Hoff DD, Ramanathan R, Borad M, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 2009; 27:abstract4525.
35. Loehr M, Bodoky G, Fö lsch U, et al. Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: a phase II trial. J Clin Oncol 2009; 27:abstract4526.
36. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966. (Pubitemid 46972777)
37. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28:3617-3622.
38. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup trial S0205. J Clin Oncol 2010; 28:3605-3610.
39. Kindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011: 12:256-262.
40. Dahan L, Bonnetain F, Ychou M, et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010; 59:1527-1534.
41. Bonnetain F, Dahan L, Maillard E, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer 2010; 46:2753-2762.
42. Boeck SH, Vehling-Kaiser U, Waldschmidt D, et al. Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): a randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2010; 28 (18S):LBA4011.
43. Epstein AS, Crosbie C, Gardos S, et al. A single-institution (MSKCC) analysis of incidence and clinical outcomes in patients with thromboembolic events and exocrine pancreas cancer. J Clin Oncol 2010; 28:316s; abstract 4062.
44. Maraveyas A, Waters J, Roy R, et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Eur J Cancer Suppl 2009; 7:362; abstract O-6503.
45. Riess H, Pelzer U,Opitz B, et al.A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial. J Clin Oncol 2010; 28:309S; abstract 4033.
46. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomized controlled multicentre phase III trial. Lancet Oncol 2005; 6:369-376. (Pubitemid 40753742)
47. Mullany S, Svingen PA, Kaufmann SH, et al. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 1998; 42:391-399. (Pubitemid 28430370)
48. Pavillard V, Formento P, Rostagno P, et al. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol 1998; 56:1315-1322. (Pubitemid 28511268)
49. Kornmann M, Fakler H, Butzer U, et al. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res 2000; 20:3259-3264.
50. Ghosn M, Farhat F, Kattan J, et al. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Am J Clin Oncol 2007; 30:15-20. (Pubitemid 46213819)
51. Zeghari-Squalli N, Raymond E, Cvitkovic E, et al. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999; 5:1189-1196. (Pubitemid 29233237)
52. Ychou M, Conroy T, Seitz JF, et al. An open label phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-flourouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003; 14:481-489. (Pubitemid 36367429)
53. Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorinmodulated fluorouracil in advanced pancreatic cancer: a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23:1228-1236. (Pubitemid 46202280)
54. Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8:82.
55. Ychou M, Desseigne F, Guimbaud R, et al. Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs. gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial [abstract 4516]. J Clin Oncol 2007; 2518S (Suppl Part I):201s.